GERMANY—NovAliX, a specialist Contract Research Organization focused on drug development, has announced a long-term strategic cooperation with Göttingen’s Max Planck Institute (MPI) for Multidisciplinary Sciences.

NovAliX and the MPI hope that this collaboration will speed up the critical process of converting scientific research and intellectual ideas into genuine cures.

This agreement will allow for critical early-stage collaboration, combining the potential of the MPI experts’ innovative discoveries with NovAliX’s award-winning scientists, and expediting the integration of academic findings into drug development.

NovAliX has evolved as a key player in the drug discovery sector, offering the organizational framework, flexibility, competence, and efficiency needed for early-stage pharmaceutical research.

This relationship with the MPI demonstrates their growing role as active players in the shifting drug discovery landscape, allowing academic research to aid in therapeutic innovation.

Speaking at the ceremony, Prof. Dr. Holger Stark, Managing Director of the MPI for Multidisciplinary Sciences, emphasized the partnership’s potential to accelerate development and revolutionary advances in the field of drug discovery.

He went on to say that the endpoint of fundamental academic research is still a long way from the early stages of drug discovery, and that bridging these phases is critical; the MPI’s and NovAliX’s complementary expertise will be critical in fostering successful clinical development.

Dr. Denis Zeyer, CEO of NovAliX, highlighted the necessity of collaboration frameworks between academia and drug discovery, drawing on his two decades of experience in the dynamic biopharmaceutical business.

He stated that it is more expensive and riskier than ever before to identify and bring novel medications to market, and that incorporating academic research further into the process will only improve the likelihood of success for therapeutic options.

Dr. Zeyer also emphasized the importance of partnerships developed over time, as seen by its longstanding collaboration with Prof. Dr. Stark at the MPI for Multidisciplinary Sciences, as well as its joint research of the topic of cryo-EM.

Dr. Ashwin Chari, Head of the Research Group of Structural Biochemistry and Mechanisms at the MPI for Multidisciplinary Sciences, acknowledged the obstacles in both the anti-infectives and oncology disciplines, but expressed confidence in translating their discoveries into impactful treatments.

Stephan Jenn, President and Co-founder of NovAliX, highlighted the collaboration with the MPI as an extraordinary opportunity to form a unique alliance that contributes not just to European, but also global, scientific advancement.

She went on to explain that bringing together the brightest brains in academia, medication development, and discovery can only lead to greater science, outcomes, and solutions.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.